Scientific Sessions 2025  /  LBS In Depth - CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3  /  CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Logo

American Heart Association

  36
  0

Final ID:

CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

  • Nicholls, Stephen  ( Victorian Heart Hospital , Clayton , Victoria , Australia )
    • Author Disclosures:
    Stephen Nicholls: DO have relevant financial relationships ; Researcher:AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience:Active (exists now) ; Consultant:Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Scribe Therapeutics, Silence Therapeutics, CSL Seqirus and Vaxxinity:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

LBS In Depth - CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Sunday, 11/09/2025 , 08:00AM - 08:30AM

Late-Breaking Science: In-Depth

More abstracts from these authors:
Will CETP inhibition PREVAIL in CVD prevention?

Nicholls Stephen

Will dual GIP and GLP1 receptor agonism SURPASS existing GLP1RAs?

Sattar Naveed, Nicholls Stephen

You have to be authorized to contact abstract author. Please, Login
Not Available